Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability, and amyloid-imaging positron emission tomography (PET) trial of AAB 001 (ELN115727) [bapineuzumab] in patients with mild to moderate Alzheimer's disease (AD).

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability, and amyloid-imaging positron emission tomography (PET) trial of AAB 001 (ELN115727) [bapineuzumab] in patients with mild to moderate Alzheimer's disease (AD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Elan Pharmaceuticals

    • Most Recent Events

    • 15 Jul 2010 Results from a substudy measuring cerebrospinal fluid tau proteins presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010 (Abstract O3-05-01), according to a Intellect Neurosciences media release.
    • 10 Jul 2010 Substudy results and pooled analysis of substudies presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
    • 01 Apr 2010 Results published in Lancet Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top